Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2

SUNG-JUN LEE1, EUN-AE KIM1, KYOUNG SEOB SONG3, MIN-JAE KIM1, DAE HYUNG LEE2, TAEG KYU KWON4 and TAE-JIN LEE1

Departments of 1Anatomy, College of Medicine and 2Obstetrics and Gynecology, Yeungnam University, Daegu; 3Department of Physiology, College of Medicine, Kosin University, Busan; 4Department of Immunology, School of Medicine, Keimyung University, Daegu, Republic of Korea

Received May 4, 2012; Accepted July 2, 2012

DOI: 10.3892/ijo.2012.1575

Abstract. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been the focus as a potential anticancer drug, because it induces apoptosis in a wide variety of cancer cells but not in most normal human cell types. In this study, we showed that combination treatment with sub-toxic doses of antimycin A (AMA), an inhibitor of electron transport, plus TRAIL induced apoptosis in human renal cancer cells, but not in normal tubular kidney cells. Treatment of Caki cells with AMA upregulated the death receptor 5 (DR5) protein and downregulated c-FLIP and Bcl-2 proteins in a dose-dependent manner. AMA-induced decrease of c-FLIPp1 and c-FLIPs proteins level which were caused by increased protein instability, which was confirmed by the result showing that treatment with a protein biosynthesis inhibitor, CHX, accelerated degradation of c-FLIPp1 and c-FLIPs proteins caused by AMA treatment. We also found that AMA induced upregulation of DR5 and downregulation of Bcl-2 at the transcriptional level. Pretreatment with N-acetyl-l-cysteine (NAC) partly recovered the expression levels of c-FLIPp1 and c-FLIPs. Collectively, this study demonstrates that AMA enhances TRAIL-induced apoptosis in human renal cancer cells by upregulation of DR5 as well as downregulation of c-FLIP and Bcl-2. Furthermore, this study shows that AMA markedly increases sensitivity to cisplatin in Caki human renal cancer cells.

Introduction

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is considered as a new potential anticancer drug. TRAIL induces apoptosis in various types of cancer cells in vitro and in vivo, but has little or no toxicity against normal cells, which is supported by the presence of large numbers of decoy receptors on normal cells (1,2). Since TRAIL is a tumor-selective and apoptosis-inducing cytokine, it is considered to be a promising new candidate for cancer prevention and treatment. However, recent studies have shown that some cancer cells are resistant to the apoptotic effects of TRAIL (3-5). TRAIL-resistant cancer cells can be sensitized by chemotherapeutic drugs and biochemical inhibitors in vitro, indicating a possibility of combination therapy. Therefore, understanding the molecular mechanisms of TRAIL resistance and ways to sensitize these cells for apoptosis by TRAIL are important issues for effective cancer therapy.

Antimycin A (AMA) inhibits succinate oxidase and nicotinamide adenine dinucleotide (NADH) oxidase and also blocks mitochondrial electron transport by binding to complex III (6). Inhibition of electron transport causes the collapse of the mitochondrial proton gradient across the mitochondrial inner membrane and the mitochondria membrane potential (MMP), thus allowing production of reactive oxygen species (ROS) as well as the release of proapoptotic molecules such as cytochrome c (7-11). Although a large number of studies have shown antitumor activity of AMA, anticancer effects of the combination of AMA and TRAIL are not clear. This study was designed to evaluate the combination treatment with AMA and TRAIL and to delineate the underlying mechanism associated with observations in vitro demonstrated by synergistic effects between AMA and TRAIL in renal cancer cells.

Materials and methods

Cells and materials. Caki cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Dulbecco’s modified Eagle’s medium (DMEM), containing 10% fetal bovine serum (FBS), 20 mM HEPES buffer and 100 μg/ml gentamicin was the culture medium used throughout the experiments. AMA and TRAIL was directly added to cell cultures at the indicated concentrations. Anti-Bcl-2, anti-procaspase-3, anti-PARP and anti-actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-c-FLIP antibody was purchased from Alexis

Key words: antimycin A, renal cancer, tumor necrosis factor-related apoptosis-inducing ligand, death receptor 5, Bcl-2, c-FLIP
Corporation (San Diego, CA, USA). Soluble recombinant TRAIL was purchased from R&D Systems (Minneapolis, MN, USA). AMA was obtained from Sigma Chemical Co. Anti-DR5 was purchased from Koma Biotech Inc. (Seoul, Korea).

Western blot analysis. Cellular lysates were prepared by suspending 1x10^6 cells in 100 µl of lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1 mM sodium orthovanadate, 15 mM MgCl₂, 0.1% Triton X-100, 25 mM MOPS, 100 µM phenylmethylsulfonyl fluoride, and 20 µM leupeptin, adjusted to pH 7.2). The cells were disrupted by sonication and extracted at 4°C for 30 min. Then, the proteins were electrotransferred to Immobilon-P membranes (Millipore Corporation, Bedford, MA, USA). Detection of specific proteins was carried out with an ECL western blotting kit according to the manufacturer’s instructions.

Flow cytometry analysis. Approximately 1x10^6 Caki cells were suspended in 100 µl of PBS, and 200 µl of 95% ethanol was added while vortexing. The cells were incubated at 4°C for 1 h, washed with PBS, and resuspended in 250 µl of 1.12% sodium citrate buffer (pH 8.4) together with 12.5 µg of RNase. Incubation was continued at 37°C for 30 min. The cellular DNA was then stained by applying 250 µl of propidium iodide (50 µg/ml) for 30 min at room temperature. The stained cells were analyzed by fluorescent activated cell sorting (FACS) on a FACScan flow cytometer for relative DNA content based on red fluorescence.

RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR). RT-PCR analysis was done as previously reported (12). The cDNA for DR5 and actin were amplified by PCR with specific primers. The sequences of the sense and anti-sense primers for DR5 were 5’-AAGACCCCTTGTGCTCG TTGT-3’ and 5’-GACACATTGACTGTCACTCCA-3’, respectively. PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide. For CHOP, the sense primer 5’-CAACTGCGAGAGTGGCAGCTGA-3’ and the antisense primer 5’-CTGATGTCCCTCCAATGTCAT-3’ (corresponding to a 536-bp region of CHOP) were used. The sequences of the sense for c-FLIPs, and c-FLIPs were 5’-CGGACTATAGTGCTG ATGG-3’ and the antisense primers were 5’-GATTATCGAGCA GATTCTCTAG-3’ (c-FLIP1) and 5’-AGATCAGGACAATGGG CATAG-3’ (c-FLIPs), respectively.

Statistical analysis. Three or more separate experiments were performed. Statistical analysis was done by paired Student’s t-test or ANOVA. A p<0.05 was considered to have pronounced difference between experimental and control groups.

Results

AMA sensitizes renal cancer cells for TRAIL-mediated apoptosis. In an attempt to search for novel strategies to overcome TRAIL resistance in cancer cells, we investigated the effect of combination treatment of AMA and TRAIL in human renal cancer cell line, Caki cells. Co-treatment of Caki cells with AMA and TRAIL resulted in a markedly increased in accumulation of the sub-G1 phase cells, compared with Caki cells treated with AMA or TRAIL alone (Fig. 1A). In addition, combination treatment of Caki cells with AMA and TRAIL led to the reduction of the protein levels of procaspase 3. The protein levels of c-FLIP1, c-FLIPs, Mcl-1 and Bcl-2 were remarkably reduced in response to combination of AMA plus TRAIL (Fig. 1B). Next, we analyzed the underlying mechanisms involved in combination treatment of AMA and TRAIL downregulates c-FLIP and Bcl-2 protein expressions but upregulates DR5 and CHOP proteins expression. To investigate the underlying mechanisms involved in combination treatment of AMA and TRAIL-mediated apoptosis, we analyzed the expression levels of various apoptosis regulating proteins using western blot assay. While protein levels of c-FLIP1, c-FLIPs, and Bcl-2 were noticeably reduced in response to AMA treatment, the levels of death receptor 5 (DR5) and CHOP proteins were increased by AMA treatment (Fig. 3A). Next, we examined whether combination treatment of AMA and TRAIL affected TCMK-1 normal renal tubular epithelial cells. Interestingly, TCMK-1 cells were resistant to AMA or TRAIL alone, and cell morphology was not significantly affected by combination treatment with AMA and TRAIL (Fig. 1D).

Combination treatment with AMA plus TRAIL-induced apoptosis is mediated via caspase-dependent pathway. We next examined whether activation of caspase pathway plays a critical role in AMA plus TRAIL-induced apoptosis. As shown in Fig. 2A, AMA plus TRAIL-induced apoptosis was completely prevented by pretreatment with the general and potent inhibitor of caspases, z-VAD-fmk, as determined by FACS analysis. We also found that z-VAD-fmk prevented all these caspase-related events including cleavage of procaspase-3 and PARP (Fig. 2B). These results suggest that combined treatment of AMA and TRAIL-induced apoptosis was mediated by caspase-dependent apoptosis pathways.

AMA downregulates c-FLIP and Bcl-2 protein expressions but upregulates DR5 and CHOP proteins expression. To investigate the underlying mechanisms involved in combination treatment of AMA and TRAIL-induced apoptosis, we analyzed the expression levels of various apoptosis regulating proteins using western blot assay. While protein levels of c-FLIP1, c-FLIPs, and Bcl-2 were noticeably reduced in response to AMA treatment, the levels of death receptor 5 (DR5) and CHOP proteins were increased by AMA treatment (Fig. 3A). Next, we examined whether AMA-mediated decrease in c-FLIP1, c-FLIPs and Bcl-2 was prevented by pretreatment of anti-oxidant N-acetyl-L-cysteine (NAC) (Fig. 3D). These results suggest that AMA-mediated degradation of c-FLIP1 and c-FLIPs proteins might be regulated by post-transcriptional levels. To further clarify the underlying mechanisms of the decreased c-FLIP1 and c-FLIPs protein levels in AMA-treated cells, we analyzed the protein stability test of c-FLIP1 and c-FLIPs. Caki cells were treated with cycloheximide (CHX) and AMA at different doses. We found that the degradation of c-FLIP1 and c-FLIPs protein were facilitated by AMA treatment (Fig. 3C), which implies that AMA treatment caused reduction of c-FLIP protein stability. We also found that AMA-induced downregulations of c-FLIP1 and c-FLIPs proteins were partly blocked by pretreatment of anti-oxidant N-acetyl-L-cysteine (NAC) (Fig. 3D). These results suggest the possibility that AMA-stimulated downregulation of c-FLIP protein appears to be partly dependent on the generation of reactive oxygen species (ROS).

Downregulation of c-FLIP1 and c-FLIPs also contributes to AMA-stimulated TRAIL-induced apoptosis. We exam-
ined whether downregulations of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> by AMA is critical in stimulating TRAIL-induced apoptosis. Overexpression of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> in Caki cells significantly attenuated AMA-facilitated TRAIL-induced apoptosis, whereas combination treatment with AMA plus TRAIL induced significant apoptosis in Caki/vector cells (Fig. 4A). Cleavage of PARP and procaspase 3 induced by combination treatment were also markedly inhibited by the overexpression of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> (Fig. 4B). These results suggest that c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> downregulations also contribute to AMA-facilitated TRAIL-induced apoptosis.

**AMA sensitizes renal cancer cells to cisplatin-mediated apoptosis.** We also investigated whether the sensitivity against chemotherapeutic agent, cisplatin, increases in Caki cells. As shown in Fig. 5A, pretreatment with AMA augmented the sensitivity to cisplatin. In addition, combination treatment of Caki cells with AMA and cisplatin led to a reduction of the protein level of procaspase 3 together with a concomitant cleavage of PARP, a substrate protein of caspases (Fig. 5B).

**Discussion**

In this study, we demonstrated for the first time that combination treatment with AMA plus TRAIL on renal cancer cells synergistically induced apoptosis. AMA-induced upregulation of DR5 or AMA-mediated downregulation of Bel-2 is controlled at the transcriptional level in a dose-dependent manner. In contrast, AMA-induced downregulation of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> is caused by facilitating degradation of c-FLIP protein. In addition, we also found that production of ROS by AMA treatment seemed to partially take part in c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> downregulations.

Induction of DR5 expression is an important underlying mechanism for sensitization of TRAIL-mediated apoptosis (13-15). In this study, we detected the induction of CHOP mRNA and DR5 mRNA expressions in AMA-treated Caki cells, indicating the possible involvement of DR5 modulation in AMA-induced sensitization of TRAIL-prompted apoptosis in these cells. However, several reports have shown that CHOP upregulates DR5 expression at the transcriptional level.
Figure 2. Combined treatment with AMA plus TRAIL induced apoptosis is mediated by caspase-dependent pathway. (A) Effect of z-VAD-fmk on apoptosis induced by AMA plus TRAIL. Caki cells were incubated with 50 µM z-VAD-fmk or solvent for 1 h before treatment with AMA (10 µM) and/or TRAIL (100 ng/ml) for 12 h. DNA contents of treated cells were evaluated after propidium iodide staining and apoptosis was measured as a sub-G1 fraction by FACS. Data are mean values obtained from three independent experiments and bars represent standard deviation. *p<0.05 compared to AMA plus TRAIL-treated cells. (B) Effect of z-VAD-fmk on caspase activation in AMA plus TRAIL treated cells. Cells were treated with the indicated concentrations of AMA and TRAIL. Equal amounts of cell lysates (40 µg) were subjected to electrophoresis and analyzed by western blotting for procaspase 3 and PARP. The proteolytic cleavage of PARP is indicated by an arrow. A representative study is shown; two additional experiments yielded similar results.

Figure 3. AMA regulates DR5 and Bcl-2 at translational level while AMA downregulates c-FLIP expressions at post-translational levels. (A) Caki cells were treated with the indicated concentrations of AMA for 12 h and were harvested in lysis buffer. Western blot analysis was performed using anti-DR5, -CHOP, -Bcl-2, -c-FLIPs, -c-FLIPL antibodies or anti-actin antibody to serve as control for the loading of protein level. (B) Caki cells were treated with the indicated concentrations of AMA for 12 h. Total-RNA was isolated and RT-PCR analysis was performed as described in Materials and Methods. A representative study is shown; two additional experiments yielded similar results. (C) Caki cells were treated with 10 µM AMA in the presence or absence of CHX for the indicated times. Western blot analysis was performed using anti-c-FLIP antibody and anti-actin antibody to serve as control for the loading of protein level. (D) Effect of NAC on protein expression induced by AMA plus TRAIL. Caki cells were incubated with 5 mM NAC or solvent for 1 h before treatment with AMA (10 µM) and/or TRAIL (100 ng/ml) for 12 h. The cells were harvested in lysis buffer, and then equal amounts of cell lysates (40 µg) were resolved by SDS-PAGE. Western blot analysis was performed using anti-c-FLIP antibody or anti-actin antibody to serve as control for the loading of protein level. Relative levels of each protein in CHX- or CHX plus AMA-treated cells were expressed as a fold of the densitometric value of each protein to that of control (right panel).
level (4,16) and we failed to detect that AMA-induced CHOP expression was related to DR5 upregulation (data not shown). Future studies will determine the mechanism of action of AMA treatment for upregulation of DR5 at the transcriptional level.

Several reagents such as compound C, rosiglitazone, LBH589 and silibinin can induce downregulation of c-FLIP and subsequent sensitization to TRAIL-induced apoptosis in different cancer cells (16-19). In this study, treatment with AMA induced downregulation of c-FLIPL and c-FLIPs and the enforced expression of c-FLIPL and c-FLIPs abrogated the induction of apoptosis by combination treatment with AMA and TRAIL. These results suggested a critical role of c-FLIPL and c-FLIPs downregulation in mediating the augmentation of TRAIL-induced apoptosis by AMA. It is generally recognized that c-FLIPL and c-FLIPs protein levels can be regulated by ubiquitin/proteasome mediated degradation (20,21) or by their transcriptional control through the NF-κB or c-Fos pathway (22,23). In our study, AMA promotes ubiquitin/proteasome-mediated degradation of c-FLIPL and c-FLIPs, leading to downregulation of c-FLIP, but not by transcriptional control. Recently, several studies have shown that ROS downregulates c-FLIP levels and increases the sensitivity to apoptotic stimuli (24,25). Therefore, we investigated whether downregulation of c-FLIPL and c-FLIPs was actually mediated by ROS signaling pathway. In the presence of NAC, the decreased levels of c-FLIPL and c-FLIPs caused by AMA were partly restored. Taken together, AMA-stimulated TRAIL-induced apoptosis appears to be dependent on the formation of ROS for downregulations of c-FLIPL and c-FLIPs.

In summary, we suggest that AMA may be a potentially important therapeutic approach for enhancing sensitivity to TRAIL via downregulations of proteins related to the inhibition of the apoptotic processes such as Bcl-2 and c-FLIP as well as upregulation of DR5 proteins. Additionally, this study showed that AMA markedly increases sensitivity to conventional cancer chemotherapeutic agent, cisplatin, in human renal cancer Caki cells.

Acknowledgements

This research was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (No. 2011-0004816).
References